PROCEPT BioRobotics (PRCT) FDA Approvals $22.56 +1.07 (+4.98%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$22.28 -0.29 (-1.26%) As of 06/26/2026 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PROCEPT BioRobotics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by PROCEPT BioRobotics (PRCT). Over the past two years, PROCEPT BioRobotics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as HYDROS™. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. HYDROS™ Robotic System FDA Regulatory Events HYDROS™ Robotic System is a drug developed by PROCEPT BioRobotics for the following indication: For Aquablation® Therapy. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - March 12,2026Provided Update Drug: HYDROS™ Robotic SystemAnnounced Date: March 12, 2026Indication: For Aquablation® TherapyAnnouncementPROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH).AI SummaryPROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, its next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is designed to provide a surgical solution that removes prostate tissue using a precision waterjet guided by robotics, aiming to improve procedure consistency and patient outcomes as the company brings the technology to more markets outside the U.S. Clinical evidence supporting Aquablation shows it can provide durable relief from BPH symptoms while preserving sexual and urinary function—outcomes that matter a great deal to patients. The company highlights Aquablation as a complete therapy option for men with BPH, backed by data that emphasize symptom improvement and quality-of-life benefits. All surgical treatments carry risks and side effects. For details on potential complications and safety information, visit https://aquablation.com/safety-information/.Read AnnouncementFDA Clearance - August 21,2024Fda Clearance Drug: HYDROS™ Robotic SystemAnnounced Date: August 21, 2024Indication: For Aquablation® TherapyAnnouncementPROCEPT BioRobotics® announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow.AI SummaryPROCEPT BioRobotics® has received FDA 510(k) clearance for its next-generation HYDROS™ Robotic System, a major step forward in robotic-assisted Aquablation therapy. This innovative platform was developed using insights from more than 50,000 procedures to deliver improved precision and efficiency during surgeries. The HYDROS system harnesses FirstAssist AI™ for treatment planning by analyzing ultrasound images to identify critical anatomy and suggest optimal procedures. It also integrates advanced image guidance through next-generation ultrasound and digital cystoscopy, ensuring detailed visualization during surgery. In addition, robotic resection with a heat-free waterjet execution offers consistent and controlled tissue removal, while the streamlined workflow enhances the overall operating room experience. These features work together to provide a more accurate and efficient treatment plan, promising better clinical outcomes for patients and a smoother process for surgeons and staff.Read Announcement PROCEPT BioRobotics FDA Events - Frequently Asked Questions Has PROCEPT BioRobotics received FDA approval? As of now, PROCEPT BioRobotics (PRCT) has not received any FDA approvals for its therapy in the last two years. What drugs has PROCEPT BioRobotics submitted to the FDA? In the past two years, PROCEPT BioRobotics (PRCT) has reported FDA regulatory activity for HYDROS™ Robotic System. What is the most recent FDA event for PROCEPT BioRobotics? The most recent FDA-related event for PROCEPT BioRobotics occurred on March 12, 2026, involving HYDROS™ Robotic System. The update was categorized as "Provided Update," with the company reporting: "PROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH)." What conditions do PROCEPT BioRobotics' current drugs treat? Currently, PROCEPT BioRobotics has one therapy (HYDROS™ Robotic System) targeting the following condition: For Aquablation® Therapy. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ACADIA Pharmaceuticals FDA EventsAethlon Medical FDA EventsAnixa Biosciences FDA EventsAxsome Therapeutics FDA EventsCapricor Therapeutics FDA EventsEnsysce Biosciences FDA EventsIncyte FDA EventsReplimune Group FDA EventsEli Lilly and Company FDA EventsAgenus FDA EventsAtea Pharmaceuticals FDA EventsKymera Therapeutics FDA EventsLexaria Bioscience FDA EventsMIRA Pharmaceuticals FDA EventsPainReform FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies MiniMed Group FDA Events TransMedics Group FDA Events AxoGen FDA Events NovoCure FDA Events Pulse Biosciences FDA Events Inspire Medical Systems FDA Events Artivion FDA Events Alpha Tau Medical FDA Events Bioventus FDA Events SS Innovations International FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:PRCT last updated on 3/16/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - March 12,2026Provided Update Drug: HYDROS™ Robotic SystemAnnounced Date: March 12, 2026Indication: For Aquablation® TherapyAnnouncementPROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH).AI SummaryPROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, its next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is designed to provide a surgical solution that removes prostate tissue using a precision waterjet guided by robotics, aiming to improve procedure consistency and patient outcomes as the company brings the technology to more markets outside the U.S. Clinical evidence supporting Aquablation shows it can provide durable relief from BPH symptoms while preserving sexual and urinary function—outcomes that matter a great deal to patients. The company highlights Aquablation as a complete therapy option for men with BPH, backed by data that emphasize symptom improvement and quality-of-life benefits. All surgical treatments carry risks and side effects. For details on potential complications and safety information, visit https://aquablation.com/safety-information/.Read Announcement
FDA Clearance - August 21,2024Fda Clearance Drug: HYDROS™ Robotic SystemAnnounced Date: August 21, 2024Indication: For Aquablation® TherapyAnnouncementPROCEPT BioRobotics® announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow.AI SummaryPROCEPT BioRobotics® has received FDA 510(k) clearance for its next-generation HYDROS™ Robotic System, a major step forward in robotic-assisted Aquablation therapy. This innovative platform was developed using insights from more than 50,000 procedures to deliver improved precision and efficiency during surgeries. The HYDROS system harnesses FirstAssist AI™ for treatment planning by analyzing ultrasound images to identify critical anatomy and suggest optimal procedures. It also integrates advanced image guidance through next-generation ultrasound and digital cystoscopy, ensuring detailed visualization during surgery. In addition, robotic resection with a heat-free waterjet execution offers consistent and controlled tissue removal, while the streamlined workflow enhances the overall operating room experience. These features work together to provide a more accurate and efficient treatment plan, promising better clinical outcomes for patients and a smoother process for surgeons and staff.Read Announcement
Free PRCT Stock Alerts